Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook?

Bristol-Myers Squibb (BMY) reported positive Phase 2 trial results for arlocabtagene autoleucel (arlo-cel) in treating relapsed and refractory multiple myeloma. The trial met its primary endpoint, showing significant overall and complete response rates. BMY raised its full-year 2026 revenue guidance to $49.0–$50.0 billion and non-GAAP EPS to $6.75–$7.00, driven by a 6% revenue increase in Q2. However, the company faces risks related to R&D costs, generic competition, and legacy revenue erosion.

Bristol Myers Squibb (BMY) awaits an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy. Egetis Therapeutics (EGTX) faces a Sept. 28 decision for Emcitate for MCT8 deficiency. Scholar Rock (SRRK), Biofrontera (BFRI), and Mirum Pharmaceuticals (MIRM) received early FDA approvals for their respective drugs. Mirum's shares rose 3% in pre-market trading.

Bristol Myers Squibb (BMY) and Egetis Therapeutics (EGTX) await FDA decisions on drug expansions. Biofrontera (BFRI), Scholar Rock (SRRK), and Mirum Pharmaceuticals (MIRM) received early approvals. BMY's Camzyos, if approved, would be the first cardiac myosin inhibitor for adolescents with oHCM. EGTX's Emcitate could be the first FDA-approved treatment for MCT8 deficiency. SRRK and BFRI shares declined post-approval, while MIRM shares rose.

Bristol Myers Squibb (BMY) presented Phase 3 trial results showing ZENBEXUS (iberdomide) with daratumumab and dexamethasone doubled minimal residual disease-negative complete response rates (41.1% vs. 20.7%) compared to standard treatment in relapsed or refractory multiple myeloma. The data were published in The Lancet Oncology and presented at IMS 2026. The FDA granted accelerated approval for ZENBEXUS in this indication on August 13.

Novartis (NVS) and Bristol-Myers Squibb (BMY) paused CAR-T cell therapy trials. NVS halted eight studies after three patient deaths, while BMY paused enrollment due to reversible inflammatory events. NVS's oncology trials continue. BMY's situation is less severe, with no deaths reported. Both companies face safety and development risks, with potential delays and increased costs.

Bristol Myers Squibb (BMS) presented Phase 3 EXCALIBER-RRMM trial data showing iberdomide (ZENBEXUS) with daratumumab and dexamethasone achieved higher MRD-negative CR rates (41%) vs. standard therapy (21%) in relapsed/refractory multiple myeloma. The FDA granted accelerated approval for this combination in August 2026. Trial continues evaluating PFS and safety.